Navigation Links
Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
Date:2/1/2017

MILPITAS, Calif., Feb. 1, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) will participate in the Leerink Partners 6th Annual Global Healthcare Conference on February 16, at Lotte New York Palace, NY.  Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer will represent the company in a session scheduled at 11:00 am (Eastern Time).

A live audio webcast of the presentation may be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at http://investors.protagonist-inc.com. A replay of the presentation will be available for 30 days following the presentation.

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways for which there are marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer preferential drug exposure in the GI tissue compartment, the potential for improved safety due to minimal exposure in the blood, improved convenience and compliance, and potentially an opportunity for the earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's oral peptide product candidates, PTG-100 and PTG-200, are based on this approach with the potential to transform the existing treatment paradigm for IBD, which includes both ulcerative colitis and Crohn's disease.

Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical development staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-leerink-partners-6th-annual-global-healthcare-conference-300400273.html


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
2. Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases
3. Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
4. Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
5. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
6. Protagonist Therapeutics Names David Liu Chief Scientific Officer
7. Research Reports Initiation on Biotech Stocks -- Portola Pharma, Tesaro, Sangamo Therapeutics, and Cerus
8. Drug Makers Stocks on Investors Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics
9. Research Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma
10. Prime Therapeutics is Certified for NCQA Utilization Management and Health Information Products - Pharmacy Benefit Information
11. Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2019)... ... December 07, 2019 , ... The 12-Step ... weekly ongoing face-to-face mutual support groups in 32 countries. At meetings members share ... members also provide several daily phone and internet meetings. This expands the means ...
(Date:12/6/2019)... ... December 06, 2019 , ... Nobilis ... psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration ... the Company to initiate its Phase 2b trial for the treatment of patients ...
(Date:12/6/2019)... Fla. (PRWEB) , ... December 06, 2019 , ... ... preferred distribution agreement with Forbidden Fruit Garden Supply LLC (a division of Horticultural ... its discerning clientele of professional growers. , FFGS is a team of ...
Breaking Medicine Technology:
(Date:12/9/2019)... ... December 09, 2019 , ... WEDI , the nation’s leading nonprofit ... exchange and a trusted advisor to the U.S. Department of Health and Human Services ... Directors, election of Officers* as well as the re-election of ten previous board members ...
(Date:12/9/2019)... ... December 09, 2019 , ... Cocoa Beach is preparing to host its 10th ... most-dazzling Santa-themed gatherings. , What began as a simple family beach day a decade ... tradition. Now, ten years in, there’s no better place for Santa to loosen up ...
(Date:12/8/2019)... ... December 08, 2019 , ... Intelligent.com, a trusted ... 52 Best Homeland Security Degree Programs for 2020. The comprehensive research guide is ... Each program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... frequently, six students in Salt Lake Community College’s (SLCC) Emergency Medical ... Rodgers and Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support ...
(Date:12/6/2019)... ... December 06, 2019 , ... Brain Sentinel, ... Baltimore, Maryland at the AES Annual Meeting. The symposium, “Fundamentals of Quantitative Surface ... methods of quantitative sEMG analysis during ictal events;, 2. Review specific sEMG patterns ...
Breaking Medicine News(10 mins):